baber/WOPTO huggingface dataset:
Patent NZ-539299-A (NZ)
Title: Assay methods for detection of a virus in an avian tissue sample
Inventor: NAIR VENUGOPAL K
IPC: C12N5/078
Filed: 2003-10-14
Abstract: A method of detecting a virus in an avian tissue sample wherein genetic material derived from the feathers of the axillary tract is tested for the presence of genetic material from the virus.
Patent NZ-539661-A (NZ)
Title: Depository system for articles such as keys being released based on sobriety via blood alcohol measurement and identification via biometric measurement
Inventor: GOTFRIED BRADLEY L
IPC: G07C9/00
Filed: 2003-10-29
Abstract: An automated depository system is described. The system comprises a sobriety detection mechanism providing a blood alcohol content reading; a storage unit for storing a deposited article, which selectively releases the deposited article based on measurements taken by the sobriety detection mechanism; and circuitry for contacting a transportation service based on measurements taken by the sobriety detection mechanism, wherein the circuitry contacts the transportation service when the blood alcohol content reading reaches a predetermined value. An associated method for storing articles using the automated depository system is also described.
Patent NZ-541121-A (NZ)
Title: Racing roller coaster ride
Inventor: CUMMINS ROBERT
Filed: 2005-07-06
Abstract: A drag racing roller coaster amusement ride has at least two sets running rails, each set having at least one running rail and an embark point. At least two carriers (109) are arranged to carry at least one rider on a respective set of running rails with the rider(s) in a substantially prone position. Each carrier is arranged to slidingly engage with the respective set of running rails to enable the carriers to traverse the ride. The ride has an indicator (109) to provide a ride commencement indication. A launch system is configured to provide a powered initial motion to each carrier. Each carrier has a ride activator controllable by a rider of the carrier to trigger the launch system to commence the ride for the carrier following the ride commencement indication. Launch systems are also disclosed.
Patent NZ-543172-A (NZ)
Title: Uptake of macromolecules
Inventor: NEW ROGER R C
IPC: A61K38/18
Filed: 2004-04-15
Abstract: Disclosed is a pharmaceutical composition comprising a mixture of: a) an active macromolecular principle; and b) a non-conjugated bile acid or salt; and c) an additive chosen from propyl gallate, butyl hydroxy anisole (BHA) and analogues and derivatives thereof, or mixtures thereof, wherein the mixture comprises at least 1% by weight of the additive c). Also disclosed is the use of a non-conjugated bile acid or salt, together with an additive chosen from propyl gallate and BHA and analogues and derivatives thereof, or mixtures thereof in the manufacture of a pharmaceutical composition for enhancing the absorption of macromolecules across the intestinal wall.
Patent NZ-543372-A (NZ)
Title: Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenoside A2A receptor
Inventor: JAKOB-ROETNE ROLAND
IPC: A61K31/428
Filed: 2004-05-21
Abstract: Disclosed are compounds of formula (I), wherein the substituents are as defined in the specification, and processes for their preparation. The compounds are useful in the treatment of diseases related to the adenosine A2A receptor.
Patent NZ-548134-A (NZ)
Title: Method and apparatus for optimizing product distribution strategies and product mixes to increase profitability in complex computer aided pricing of products and services
Inventor: FENG YAN
IPC: G06F3/0482
Filed: 2004-11-22
Abstract: A software application for creating, monitoring, and optimizing deals in an automated pricing system for calculating pricing for items and item orders is disclosed. The pricing system has a server node for serving pricing information, a pricing application for calculating the pricing information served, and a data repository for storing at least one pricing data model and rules for manipulating the model. The software application comprises: (a) a graphical user interface for accessing and directing the application; (b) a set of advisory factors having rules and attributes associated thereto; (c) a set of related calculating sequences for calculating results using at least one of the advisory factors in sequence; and (d) at least one ranking factor for optimizing results returned by the set of calculating sequences, wherein a user operating through the graphical user interface initiates a set of calculation sequences, related by factor, to one or more possible options associated with a deal. The calculation sequences cooperate to return a list of data structures for user consideration, where the list of data structures is ranked according to one or more goal-based attributes.
Patent NZ-548938-A (NZ)
Title: Topical macrocyclic lactone formulation
Inventor: ZUPAN JACOB A
Filed: 2006-08-04
Abstract: Disclosed is a composition including: a macrocyclic lactone; and aromatic solvent; polybutene; a pharmacologically acceptable oil; and a spreading agent selected from the group consisting of isopropyl myristate, polydimethyl-cyclosiloxane, PEG-40 sorbitan peroleate, cyclomethicon, isopropyl palmitate, ethanol, or a mixture thereof; and wherein the macrocyclic lactone is moxidectin. Also disclosed are methods for the treatment, prevention or control of helminth, acarid or arthropod infection in non-human animals using the invention of claim 1.
Patent NZ-551660-A (NZ)
Title: Pyrrazolo-pyrimidine derivatives and their use in diseases or conditions where mGluR2 activation plays a role
Inventor: WOLTERING THOMAS JOHANNES
IPC: C07D487/04
Filed: 2005-06-13
Abstract: Disclosed is a compound of formula (I), and pharmaceutically acceptable salts thereof, wherein p is 0 or 1, R3 is lower alkyl, hydroxy-lower alkyl or NRaRb, and wherein the other substituents are disclosed in the specification. Also disclosed is the use of the compound for treating diseases or disorders in which mGluR2 activation plays a role, such as the prevention or treatment of acute andor chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficits, and glioma.
Patent NZ-564466-A (NZ)
Title: Helix 12 directed non-steroidal antiandrogens
Inventor: LABRIE FERNAND
IPC: A61K31/4166
Filed: 2006-06-16
Abstract: Disclosed is a compound of the pictured formula, or a salt thereof, where R2 and R3 are either separate substituents or may join together to form a fused ring, n is 0-3, D is a 5-6 membered saturated, nitrogen containing ring, E is phenylene or mono-substituted pyridiyl, and where the rest of the substituents are as defined in the specification. Also disclosed is the use of the compound for treating prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia, male baldness, polycystic ovarian syndrome, precocious puberty, hyperandrogenic syndromes, diseases related to loss of androgenic stimulation selected from muscle atrophy and weakness, skin atrophy, bone loss, anemia, atherosclerosis, cardiovascular disease, loss of energy, loss of well being, type 2 diabetes or abdominal fat accumulation.
Patent NZ-566769-A (NZ)
Title: Electromuscular incapacitation device with specific low power electric waveform with high frequency
Inventor: STETHEM KENNETH J
IPC: F41B15/04
Filed: 2006-08-23
Abstract: A handheld apparatus (10) for temporarily incapacitating a subject using pulsed electric current applied to the muscles includes a circuit for generating a pulsed, low-power electric waveform; a plurality of electrical contacts (E) for delivering the waveform to a subject; and a switch (20) to selectively activate the circuit. The waveform has a frequency value in a range of about 40 Hz to about 80 Hz and is generated over a time period sufficient to induce involuntary muscular contraction with non-injurious muscle effects. More particularly the peak voltage is limited to be less than 1 kV, the peak current is less than 1A, the pulse duration is between 3 microseconds and 1 millisecond.
Patent NZ-566787-A (NZ)
Title: Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
Inventor: ECKHARDT MATTHIAS
IPC: C07D309/10
Filed: 2006-09-07
Abstract: The disclosure relates to a crystalline hydrate of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and to crystalline complexes between 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments.
Patent NZ-566877-A (NZ)
Title: Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
Inventor: KEIL STEFANIE
IPC: A61K31/421
Filed: 2006-09-26
Abstract: Disclosed are 2-phenyl-[1,2,4]oxadiazol-5-one derivatives as represented by formula (I), wherein B is C(R4) or N; R1, R2, R3 and R4 are independently selected from the group consisting of H, halogen, alkyl, alkylene-O-alkylene-H, cycloalkyl, SCH3, and CN, where in the alkyl and alkylene groups are unsubstituted or 1- to 5-fold substituted by F; or R2 and R3 together with the carbon atoms to which they are bonded form an aryl or heteroaryl ring; X is O, S, S(O), S(O)2, O-CH-2, S-CH2, CH2-O, or CH2-S; one of U and V is N the other is S or O; Z is a bond, alkylene, alkenylene, alkylidene, or alkylene-O-alkyl; A is cycioalkyl, heterocycloalkyl, heterocycloalkenyl or a heteroaryl ring; and wherein the other substituents are as described herein. Also disclosed is the use of the compounds as defined above for the preparation of a medicament for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders.
Patent NZ-569307-A (NZ)
Title: Padlock with a removable shackle
Inventor: HAYTER STEWART JOHN
Filed: 2008-06-23
Abstract: A padlock with a selectively removable shackle is disclosed. The padlock has a body (12), a shackle (14), and a cylinder for unlocking the padlock. There is a locking element (46) that has a locking position in which withdrawal of the shackle from the body is prevented, an unlocking position in which the shackle may be withdrawn but not completely separated from the body, and a releasing position in which the shackle may be completely separated from the body. Locking means move the locking element into the locking position when the shackle or part thereof is inserted, with the locking means able to be moved by operating the cylinder to allow the locking element to adopt the unlocking or releasing position. A selector (70) can be operated from externally of the body to adopt a first position in which the selector allows the locking element to adopt the locking and unlocking positions but prevents the locking element from adopting the releasing position, and a second position in which the selector allows the locking element to adopt the releasing position.
Patent NZ-570078-A (NZ)
Title: Piperidine and piperazine derivatives
Inventor: LI XIAOYUAN
IPC: A61K31/497
Filed: 2007-01-22
Abstract: Disclosed is a compound of general formula (Ia) in which: R1 represents 2,3-dihydrobenzofuran-5-yl or a phenyl group that is substituted by one, two or three substituents selected independently from an alkoxy group, a hydroxyalkoxy group, a alkylsulfanyl group, a alkylsulfonyl group and a haloalkylsulfonyl group; A1 represents (CH2)m; m is 2, 3, 4 or 5; X is CH or N; n is 1, 2, 3, 4 or 5, R2 is hydrogen, (alkyl or phenylalkyl, or is as defined for R3; and R3 is indan-1-yl, indan-2-yl, 1,2,3,4-tetrahydronaphth-1-yl, or 1,2,3,4-tetrahydronaphth-2-yl, each of which may bear a hydroxyl substituent on a non-aromatic carbon atom; cycloalkyl; or a phenyl group or a pharmaceutically acceptable salt thereof, e.g. 1-[2-(2-Fluorophenoxy)ethyl]-4-[ 5 3-(3,4,5-trimethoxyphenyl)propyl]piperazine dihydrochloride, 4-(3-{ 4-[2-(4-Fluorophenoxy)ethyl]piperazin-1-yl} -propyl)phenol dihydrochloride, 1-[4-(3,4-Dimethoxyphenyl)butyl]-4-[2-(4-fluorophenoxy)ethyl]piperazine dihydrochloride, and 1-[2-(4-Fluorophenoxy)-ethyl]-4-[4-(4-methoxyphenyl)butyl]piperazine dihydrochloride for treating a neurological disorder selected from cerebral deficits subsequent to cardiac bypass surgery and grafting, cerebral ischemia; spinal cord trauma; head trauma; multiple sclerosis, Alzheimer's Disease; Huntington's Chorea; amyotrophic lateral sclerosis; AIDS induced dementia; muscular spasms; convulsions; drug tolerance, withdrawal, and cessation; ocular damage and retinopathy; cognitive disorders; idiopathic and drug-induced Parkinson's Disease; pain; and movement disorders such as tardive dyskinesia; or a psychiatric disorder selected from schizophrenia, anxiety, panic attack, stress-related disorder, depression, bipolar disorders, psychosis, and obsessive compulsive disorders in a patient.
Patent NZ-575687-A (NZ)
Title: A block for chemically dosing a stream of fluid and an apparatus for housing the block
Inventor: MITCHELL GRANT
IPC: A01N25/02
Filed: 2007-10-05
Abstract: Disclosed is an apparatus for housing a block for chemically dosing a stream of fluid flowing past at least one surface of the block, by dissolution and/or erosion of the block, the block consisting of one or more active ingredients and a solid carrier of polyethylene glycol for carrying the one or more active ingredients, the apparatus including a chamber for the block to reside in, the chamber having an inlet and an outlet to enable the stream of fluid to flow there through, wherein the chamber is shaped to enable the block to reside therein with opposing side walls of the block abutting the side walls of the chamber such that, in use, the at least one surface of the block is dissolved and/or eroded without a substantial change in the area of the at least one surface thereby providing a constant rate of chemical dosing to the stream of fluid for a given flow rate.
Patent NZ-575960-A (NZ)
Title: Process for the deoxygenation of feedstocks containing carboxylic acids / esters to produce hydrocarbons involving a supported Cobalt Molybdenum catalyst
Inventor: GUDDE NICHOLAS JOHN
IPC: C10G3/00
Filed: 2007-10-04
Abstract: Disclosed is a process for the deoxygenation of feedstocks containing carboxylic acids / esters to produce hydrocarbons involving a supported Cobalt Molybdenum catalyst, said process comprises the steps of: (a) feeding hydrogen and a reaction composition comprising a carboxylic acid and/or derivative thereof (particularly biological oils, vegetable oils or fats) to a reactor; (b) maintaining conditions within the reactor such that the hydrogen reacts with the carboxylic acid and/or derivative thereof to produce one or more C1 compounds selected from one or more of carbon monoxide (CO), carbon dioxide (CO2) and methane (CH4), and one or more product hydrocarbons derived from the carboxylic acid and/or derivative thereof, in which the reaction between hydrogen and carboxylic acid and/or derivative thereof is catalysed using a supported CoMo catalyst, wherein the total pressure in the reactor is 31 bara (3.1 MPa) or less and wherein the reaction temperature is in the range of from 200 to 430°C; (c) removing from the reactor a product stream comprising unreacted hydrogen, the one or more C1 compounds, and one or more product hydrocarbons; (d) feeding the product stream to a flash separator, from which a vapour fraction comprising C1 compounds and unreacted hydrogen is separated from a liquid fraction comprising the one or more product hydrocarbons; and (e) recycling at least a portion of the unreacted hydrogen in the vapour fraction to the reactor; wherein the process comprises controlling one or more of the total pressure in the reactor, the hydrogen partial pressure in the reactor, the reaction temperature, the molar ratio of carboxylate groups to hydrogen in the reactor and the space velocity of the reaction composition over the catalyst such that: the molar ratio of C1 compounds produced by the reaction to the carboxylate groups present in the carboxylic acid and/or derivative thereof in the reaction composition as fed to the reactor is maintained above a value of 0.37:1, and the molar ratio of carbon dioxide to the sum of carbon monoxide and methane is maintained above a value of 0.58:1.
Patent NZ-579478-A (NZ)
Title: Epha3 antibodies for the treatment of solid tumors
Inventor: MURONE CARMELINA
IPC: A61P35/00
Filed: 2008-03-10
Abstract: Disclosed are methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.
Patent NZ-581043-A (NZ)
Title: Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
Inventor: SINNOTT ROBERT A
IPC: A23L33/00
Filed: 2008-05-09
Abstract: Disclosed is a dietary supplement comprising: probiotic bacteria and natural polysaccharides, wherein the bacteria are capable of processing the polysaccharides into processed polysaccharides that constitute a nutritional supplement; the natural polysaccharides characterized in that they comprise acetylated mannan, larch arabinogalactan and one or more natural polysaccharides selected from glucomannans, aloe glucomannan, konjac glucomannan, galactomannans, arabinogalactans, algal polysaccharides, fucoidans, fungal polysaccharides, fungal glucomannans, gum tragacanth, gum ghatti, xanthan gum, guar gum, and gum acaci.
Patent NZ-584683-A (NZ)
Title: Neisseria meningitidis serogroup B vaccine formulations
Inventor: CONTORNI MARIO
IPC: A61K39/095
Filed: 2008-10-17
Abstract: Disclosed is a method of preparing a liquid adjuvated immunogenic composition, said method comprising mixing at the time of delivery: (i) an adjuvant comprising an oil-in-water emulsion and (ii) a lyophilised antigenic composition comprising at least one N.meningitidis immunogen from a serogroup B strain of N.meningitidis.
Patent NZ-590132-A (NZ)
Title: Dosage regime for treating intraocular neovascular diseases with VEGF
Inventor: SHAMS NAVEED
IPC: A61K39/00
Filed: 2005-10-21
Abstract: Provided is the use of a VEGF antagonist in the manufacture of a medicament for treating intraocular neovascular disease in a human by intravitreal administration wherein the VEGF antagonist is a protein antagonist, and wherein the medicament is formulated for administration in a method comprising: a) administering three first individual doses of the VEGF antagonist at one month intervals; followed by b) administering a number of second individual doses of the antagonist, wherein the second individual doses are administered less frequently than the first individual doses.
Patent NZ-591845-A (NZ)
Title: 3h-imidazo[4,5-b]pyridine-6-carboxamides as anti -inflammatory agents
Inventor: PFAU ROLAND
IPC: A61K31/4188
Filed: 2009-09-25
Abstract: Disclosed are 2-(phenylamino)-3H-imidazo[4,5-b]pyridine-6-carboxamide derivatives as represented by te general formula (I), wherein Q2, Q3, Q3a and Q4 each represent C(R2), C(R3), C(R3a) and C(R4) or any one or two of Q2, Q3, Q3a and Q4 may alternatively and independently represent N; and wherein the remaining substituents are as defined herein. Representative compounds include 2-(2,6-dichloro-phenylamino)-3H-imidazo[4,5-b]pyridine-6-carboxylic acid (4-chloro-3-fluoro-phenyl)-amide; N-(4-bromophenyl )-2 -(2,6-dichlorophenylamino)-5-methoxy-3-methyl-3H-imidazo[4,5-b]pyridine-6-carboxamide; 2-(2,6-dichlorophenylamino)-N-(spiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridine-6-carboxamide; 2-(4-trifluoromethyl-pyridin-3-ylamino)-5-(2,2-difluoro-ethoxy)-N-(trans-4-trifluoromethyl-cyclohexyl)-3-methyl-3H-imidazo[4,5-b]pyridine-6-carboxamide and 2-(2,6-dichloro-4-fluoro-phenylamino)-5-(2,2,2-trifluoro-ethoxy)-N-(2,2,3,3,4,4,5,5,5-nonafluoropentyl)-3-methyl-3H-imidazo[4,5-b]pyridine-6-carboxamide. Further disclosed is a pharmaceutical which comprises a compound as defined above for the treatment of asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, inflammatory bowel disease, irritable bowel syndrome, pain, inflammatory pain, fever, migraine, headache, low back pain, fibromyalgia, a myofascial disorder, a viral infection, a bacterial infection, a fungal infection, dysmenorrhea, a burn, a surgical or dental procedure, a malignancy, hyperprostaglandin E syndrome, classic Bartter syndrome, atherosclerosis, gout, arthritis, osteoarthritis, juvenile arthritis, rheumatoid arthritis, rheumatic fever, ankylosing spondylitis, Hodgkin's disease, systemic lupus erythematosus, vasculitis, pancreatitis, nephritis, bursitis, conjunctivitis, iritis, scleritis, uveitis, wound healing, dermatitis, eczema, psoriasis, stroke, diabetes mellitus, a neurodegenerative disorder, an autoimmune disease, an allergic disorder, rhinitis, an ulcer, coronary heart disease, sarcoidosis, any other disease with an inflammatory component, osteoporosis, osteoarthritis, Paget's disease, a periodontal disease or a cancer.
Patent NZ-592237-A (NZ)
Title: Ostomy appliance with moldable adhesive
Inventor: NGUYEN-DEMARY TINH
IPC: A61F5/443
Filed: 2009-11-30
Abstract: 592237 A body fitment for an ostomy appliance comprises an adhesive wafer (10) including a moldable region (10a) shapable by the user. A removable release liner (20) covering an external adhesive surface of the wafer is configured to permit molding of the moldable region by manually manipulating the adhesive through the release liner, and/or with removable segments. In an alternative form, an interior release liner is removable through the entrance aperture of the wafer, by pulling on a grip portion that protrudes through the entrance aperture. In an alternative form, an ostomy pouch includes a finger pocket in a front pouch wall, for permitting insertion of a finger tip for molding the moldable region of an adhesive wafer that is secured around a stomal aperture in a rear pouch wall. At least a portion (20a) of the release liner covering the moldable region of the adhesive wafer is made of stretchable material that permits deformation of the release liner to accommodate manipulation of the adhesive through the release liner.
Patent NZ-594105-A (NZ)
Title: Novel macrocyclic inhibitors of hepatitis c virus replication
Inventor: SEIWERT SCOTT D
IPC: A61K38/00
Filed: 2006-07-17
Abstract: Disclosed is a compound of Formula (1), and a method for making said compound comprising intermixing compound (1a) with TBTU and DIEA. Further disclosed is a pharmaceutical composition comprising a compound of formula (1), and the use of said compound in the manufacture of a medicament for treating hepatitis C.
Patent NZ-597534-A (NZ)
Title: Method for treating a patient in need of aspirin therapy
Inventor: PLACHETKA JOHN R
IPC: A01N43/40
Filed: 2010-06-24
Abstract: 597534 Disclosed herein is the use of a pharmaceutical composition in unit dosage form for the preparation of a medicament for the treatment of pain or inflammation in a subject, wherein the unit dosage form is a tablet comprising a core and two or more layers, in which: the core comprises aspirin or a pharmaceutically acceptable salt thereof, a first layer surrounds the core and has a coating substantially insoluble in aqueous medium at a pH below 3.5 and at a temperature of 37 °C; and at least one second layer comprises omeprazole or pharmaceutically acceptable salt thereof, that is immediately soluble when the dosage form is placed in an aqueous medium, independent of pH, in an amount effective to raise the gastric pH of the patient to at least 3.5 upon administration of one or more unit dosage forms, said second layer surrounding the coating of the first layer, wherein said treatment is to be continued for a period of at least 14 days, and wherein said treatment reduces the incidence of dyspepsia associated symptoms in said subject.